-transparent.png){kind=logo}
In a double-blind investigation N-methyl-N-(beta-hydroxyethyl) guanidine O-phosphate (creatinol O-phosphate, COP) was checked versus a reference substance (solvent of COP) on volunteers affected by ischemic heart disease with persistent ventricular premature beats (VPB). COP was able to reduce VPB by 50--100% in 85% of the volunteers treated with this drug. This fact and the virtual absence of side-effects of COP lead the authors to the conclusion that COP merits more extensive investigations in this field in view of its clinical employment alone or in association with specific antiarrhythmic agents.
Related Publications
F Di Maio, and
A Neri, and
P Soccorsi, and
A Sciacca
January 1979,
Arzneimittel-Forschung,
F Di Maio, and
A Neri, and
P Soccorsi, and
A Sciacca
January 1978,
Bollettino della Societa italiana di cardiologia,
F Di Maio, and
A Neri, and
P Soccorsi, and
A Sciacca
September 1971,
Minerva cardioangiologica,
F Di Maio, and
A Neri, and
P Soccorsi, and
A Sciacca
January 1979,
Arzneimittel-Forschung,
F Di Maio, and
A Neri, and
P Soccorsi, and
A Sciacca
June 1975,
Current therapeutic research, clinical and experimental,
F Di Maio, and
A Neri, and
P Soccorsi, and
A Sciacca
February 1987,
Japanese circulation journal,
F Di Maio, and
A Neri, and
P Soccorsi, and
A Sciacca
December 1965,
Il Farmaco; edizione scientifica,
F Di Maio, and
A Neri, and
P Soccorsi, and
A Sciacca
June 1970,
La Clinica terapeutica,
F Di Maio, and
A Neri, and
P Soccorsi, and
A Sciacca
September 1972,
La Clinica terapeutica,
F Di Maio, and
A Neri, and
P Soccorsi, and
A Sciacca
March 1984,
The American journal of cardiology,
